Track topics on Twitter Track topics that are important to you
Chiesi Group has ended its four-year-old collaboration with uniQure to co-develop and license a gene therapy for hemophilia B and has returned its development and commercialization rights to the gene therapy candidate in Europe and other areas, uniQure acknowledged. In a statement yesterday, Chiesi CEO Ugo Di Francesco cited unspecified “recent changes in our strategic priorities” for his company’s decision to terminate its co-development and license agreement with uniQure for Glybera ® (alipogene tiparvovec). The termination gives uniQure full rights to AMT-060, its lead gene therapy candidate for patients with hemophilia B—but no partner to co-develop the gene therapy as it heads into pivotal trials. “By regaining unencumbered, global rights to a late-stage program that has demonstrated significant clinical benefit for patients with hemophilia B, we believe uniQure is better positioned to accelerate the global clinical development plan, maximize shareholder return on our pipeline, and take ...NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...